Explore
Validate
Learn11-7229-42
antibody from Invitrogen Antibodies
Targeting: IL22
IL-21, IL-22, IL-D110, IL-TIF, ILTIF, MGC79382, MGC79384, TIFa, TIFIL-23, zcyto18
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [9]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11-7229-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- IL-22 Monoclonal Antibody (22URTI), FITC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The 22URTI monoclonal antibody reacts with human interleukin(IL)-22. IL-22 is a 20 kDa member of the IL-10 cytokine family that is secreted primarily by Th17 and NK cells. Nevertheless, other T cells have also been shown to produce IL-22. In in vitro Th17 cultures, induction of IL-22 expression is greater in response to IL-23 than IL-6 or TGF beta, suggesting that this cytokine may be secreted by more fully differentiated Th17 cells in vivo. A heterodimer consisting of IL-10R2 and IL-22R1 serves as the receptor for IL-22.
- Conjugate
- Green dye
- Antibody clone number
- 22URTI
- Concentration
- 5 µL/Test
Submitted references Altered T-Cell Subsets are Associated with Dysregulated Cytokine Secretion of CD4(+) T Cells During HIV Infection.
Decreased Frequencies of Gamma/Delta T Cells Expressing Th1/Th17 Cytokine, Cytotoxic, and Immune Markers in Latent Tuberculosis-Diabetes/Pre-Diabetes Comorbidity.
TIRC7 inhibits Th1 cells by upregulating the expression of CTLA‑4 and STAT3 in mice with acute graft‑versus‑host disease.
Differential influences of the BPA, BPS and BPF on in vitro IL-17 secretion by mouse and human T cells.
Accumulation of T-helper 22 cells, interleukin-22 and myeloid-derived suppressor cells promotes gastric cancer progression in elderly patients.
Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis.
Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses.
Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis.
Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage.
Wang D, Jiang Y, Song Y, Zeng Y, Li C, Wang X, Liu Y, Xiao J, Kong Y, Zhao H
Journal of inflammation research 2021;14:5149-5163
Journal of inflammation research 2021;14:5149-5163
Decreased Frequencies of Gamma/Delta T Cells Expressing Th1/Th17 Cytokine, Cytotoxic, and Immune Markers in Latent Tuberculosis-Diabetes/Pre-Diabetes Comorbidity.
Kathamuthu GR, Kumar NP, Moideen K, Menon PA, Babu S
Frontiers in cellular and infection microbiology 2021;11:756854
Frontiers in cellular and infection microbiology 2021;11:756854
TIRC7 inhibits Th1 cells by upregulating the expression of CTLA‑4 and STAT3 in mice with acute graft‑versus‑host disease.
Zhu F, Qiu T, Zhu S, Zhao K, Chen C, Qiao J, Pan B, Yan Z, Chen W, Liu Q, Wu Q, Cao J, Sang W, Zeng L, Sun H, Li Z, Xu K
Oncology reports 2020 Jul;44(1):43-54
Oncology reports 2020 Jul;44(1):43-54
Differential influences of the BPA, BPS and BPF on in vitro IL-17 secretion by mouse and human T cells.
Malaisé Y, Le Mentec H, Sparfel L, Guzylack-Piriou L
Toxicology in vitro : an international journal published in association with BIBRA 2020 Dec;69:104993
Toxicology in vitro : an international journal published in association with BIBRA 2020 Dec;69:104993
Accumulation of T-helper 22 cells, interleukin-22 and myeloid-derived suppressor cells promotes gastric cancer progression in elderly patients.
Chen X, Wang Y, Wang J, Wen J, Jia X, Wang X, Zhang H
Oncology letters 2018 Jul;16(1):253-261
Oncology letters 2018 Jul;16(1):253-261
Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis.
Fu D, Song X, Hu H, Sun M, Li Z, Tian Z
Molecular medicine reports 2016 Jun;13(6):4606-12
Molecular medicine reports 2016 Jun;13(6):4606-12
Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses.
Wang WB, Yen ML, Liu KJ, Hsu PJ, Lin MH, Chen PM, Sudhir PR, Chen CH, Chen CH, Sytwu HK, Yen BL
Stem cell reports 2015 Sep 8;5(3):392-404
Stem cell reports 2015 Sep 8;5(3):392-404
Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis.
Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, Hu NW, Ma DX, Li ZF, Yang Q, Li W, Li JM
PloS one 2012;7(4):e31000
PloS one 2012;7(4):e31000
Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage.
Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, Pierce R, McClanahan TK, Sadekova S, de Waal Malefyt R
Journal of immunology (Baltimore, Md. : 1950) 2010 Jul 1;185(1):679-87
Journal of immunology (Baltimore, Md. : 1950) 2010 Jul 1;185(1):679-87
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Intracellular staining of CD4-enriched Th17-polarized (using Human IL-23 Recombinant Protein (Product # 14-8239-63), normal human peripheral blood cells with Anti-Human CD4 eFluor® 450 (Product # 48-0049-42) and Anti-Human IL-22 FITC. Cultures were treated with Protein Transport Inhibitor Cocktail (500X) (Product # 00-4980-03) alone (left) or Cell Stimulation Cocktail (plus protein transport inhibitors) (500X) (Product # 00-4975-03) (right) for 5 hours prior to intracellular staining using the Intracellular Fixation & Permeabilization Buffer Set (Product # 88-8824-00). Live cells in the lymphocyte gate, as determined by Fixable Viability Dye eFluor® 780 (Product # 65-0865-14), were used for analysis.
- Conjugate
- Green dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Inhibition of RUNX3 regulates the frequencies of Th17 and Th22 in CD4 + T cells from patients with psoriasis. The frequencies of Th17 and Th22 cells in CD4 + T cells from patients with psoriasis transfected with RUNX3 siRNA or an siRNA control was detected using flow cytometry. (A and B) Flow cytometric analysis of Th17 in CD4 + T cells from patients with psoriasis. The percentages of cells in the Q2 region represent the percentage of Th17 cells. (C and D) Flow cytometric analysis of Th22 in CD4 + T cells from patients with psoriasis. The percentages of cells in the Q2 region represent the percentage of Th22 cells. (E) Percentages of Th17 and Th22 cells in CD4 + T cells from patients with psoriasis transfected with RUNX3 siRNA or an siRNA control. Data are presented as the mean +- standard deviation of three experiments. * P
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Decreased frequencies of gammadelta T cells expressing Th17 cytokines in LTB comorbidities. PBMCs were either untreated or treated with Mtb or positive control antigens for 18 h. The absolute (unstimulated, UNS) and antigen-stimulated (PPD, WCL, P/I) net frequencies of Th17 (IL-17A, IL-17F, IL-22) cytokines were shown in LTB DM (n = 20), LTB PDM (n = 20), and LTB NDM (n = 20) groups. Geometric mean values were represented using bars, and every circle denotes a single individual. Kruskal-Wallis test with multiple Dunn's comparison was used to determine the p values.
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 8. Changes in cytokines in recipient mice on day 21 post-allo-BMT. (A) Changes in IFN-gamma-positive Th1 in recipient mice on day 21 post-allo-BMT as determined via flow cytometry. (B) Changes in IL-4-positive Th2 cells in recipient mice on day 21 post-allo-BMT as determined via flow cytometry. (C) Changes in IL-17-positive Tg17 cells in recipient mice on day 21 post-allo-BMT as determined via flow cytometry. (D) Changes in IL-22-positive Th22 cells in recipient mice on day 21 post-allo-BMT as determined via flow cytometry. Allo-BMT, allogeneic bone marrow transplant; Th, T helper; IFN, interferon; IL, interleukin.
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Multipotent Human Mesenchymal Stromal Cells (hMSCs) Suppress Th17 Responses (A-D) Human peripheral blood CD3 + leukocytes (PBLs) (A, representative data; B, pooled data of 17 PBL donors co-cultured with all three hMSC donors) or CD3 + CD4 T cells (C, representative data; D, pooled data of 11 PBL donors co-cultured with all three hMSC donors) were co-cultured without (left) or with (right) hMSCs ex vivo, followed by PMA/ionomycin stimulation for 6 hr. (E-H) IL-17A production in ex-vivo-cultured CD3 + T cells was assessed by intracellular staining. IL-17A and IFN-gamma production in CD3 + PBLs (E, representative data; F, pooled data) or CD3 + CD4 T cells (G, representative data; H, pooled data) without and with co-culture of hMSCs was analyzed by flow cytometry. Representative intracellular staining is shown for IL-17A + IFN-gamma - - CD3 + T cells (R3 region) and IL-17A + IFN-gamma + (R5 region) CD3 + T cells, and pooled data from PBLs (n = 4) or CD4 T cells (n = 4) co-cultured with two hMSC donors (donors A and B) are provided in (F) and (H), respectively. Gray bars represent the percentages of IL-17A + IFN-gamma - - CD3 + T cells, whereas white bars represent the percentages of IL-17A + IFN-gamma + T cells. (I and J) IL-22 production in four donors of CD3 + CD4 T cells (I, representative data; J, pooled data) without and with co-culture of two donors of hMSCs (donors A and B) was assessed by intracellular staining. Cell percentages are denoted in the dotplot quadran
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1. Flow cytometric analysis was used to determine the distribution of Th22, Th17 and Th1 cells in EGC, HE and HY ( Fig. 1 ). Flow cytometric analysis of Th22, Th17 and Th1 cells in peripheral whole blood from EGC (n=39), HE (n=32) and HY (n=31). (A) Lymphocytes were gated in P1 using flow cytometry. CD4 + IFN-gamma - lymphocytes were gated in P2 using flow cytometry, and representative results of flow cytometric analyses for (B) Th1 (CD4 + IFN-gamma + ), (C) Th22 (CD4 + IFN-gamma - IL-17 - IL-22 + ) and Th17 (CD4 + IFN-gamma - IL-17 + IL-22 - ) cells in the three groups of subjects are presented. The number of cells stained in EGC, HE and HY in P2 were 2,654, 4,696 and 5,185, respectively. The proportion of (D) Th22, (E) Th17 and (F) Th1 cells in the three groups of subjects. The proportion of (G) Th22 and (H) Th17 cells in peripheral whole blood derived from patients with early (n=13) or advanced (n=26) gastric cancer. The association between the proportion of (I) Th22 and Th17 cells, (J) Th22 and Th1 cells, and (K) Th17 and Th1 cells, in peripheral whole blood of all subjects. *P
- Conjugate
- Green dye
